JP2017537100A5 - - Google Patents

Download PDF

Info

Publication number
JP2017537100A5
JP2017537100A5 JP2017528520A JP2017528520A JP2017537100A5 JP 2017537100 A5 JP2017537100 A5 JP 2017537100A5 JP 2017528520 A JP2017528520 A JP 2017528520A JP 2017528520 A JP2017528520 A JP 2017528520A JP 2017537100 A5 JP2017537100 A5 JP 2017537100A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
independently selected
oxo
carbocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017528520A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537100A (ja
JP6771464B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/062794 external-priority patent/WO2016086200A1/en
Publication of JP2017537100A publication Critical patent/JP2017537100A/ja
Publication of JP2017537100A5 publication Critical patent/JP2017537100A5/ja
Application granted granted Critical
Publication of JP6771464B2 publication Critical patent/JP6771464B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017528520A 2014-11-27 2015-11-25 Cbpおよび/またはep300インヒビターとしての、4,5,6,7−テトラヒドロ−1h−ピラゾロ[4,3−c]ピリジン−3−アミン化合物 Active JP6771464B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/092380 2014-11-27
CN2014092380 2014-11-27
CNPCT/CN2015/092965 2015-10-27
CN2015092965 2015-10-27
PCT/US2015/062794 WO2016086200A1 (en) 2014-11-27 2015-11-25 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors

Publications (3)

Publication Number Publication Date
JP2017537100A JP2017537100A (ja) 2017-12-14
JP2017537100A5 true JP2017537100A5 (enExample) 2019-01-10
JP6771464B2 JP6771464B2 (ja) 2020-10-21

Family

ID=55024234

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017528520A Active JP6771464B2 (ja) 2014-11-27 2015-11-25 Cbpおよび/またはep300インヒビターとしての、4,5,6,7−テトラヒドロ−1h−ピラゾロ[4,3−c]ピリジン−3−アミン化合物

Country Status (5)

Country Link
US (2) US9763922B2 (enExample)
EP (2) EP3224258B1 (enExample)
JP (1) JP6771464B2 (enExample)
CN (1) CN107531690B (enExample)
WO (1) WO2016086200A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40940A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
EP3218376B1 (en) 2014-11-10 2019-12-25 Genentech, Inc. Bromodomain inhibitors and uses thereof
SG11201704089UA (en) * 2014-12-05 2017-06-29 H Lee Moffitt Cancer Ct & Res Bromodomain inhibitor as adjuvant in cancer immunotherapy
JP6709792B2 (ja) 2015-01-29 2020-06-17 ジェネンテック, インコーポレイテッド 治療用化合物およびその使用
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
WO2017205536A2 (en) * 2016-05-24 2017-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
MA45146A (fr) 2016-05-24 2021-03-24 Constellation Pharmaceuticals Inc Dérivés de pyrazolopyridine pour le traitement du cancer
AU2017302554A1 (en) 2016-07-25 2019-01-31 Epizyme, Inc. CREBBP related cancer therapy
GB201617627D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
EP3643703A4 (en) * 2017-06-21 2020-12-23 Daiichi Sankyo Co., Ltd. EP300 / CREBBP INHIBITOR
WO2019055877A1 (en) * 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
BR112020008765A2 (pt) 2017-11-02 2020-10-20 Aicuris Gmbh & Co. Kg indol-2-carboxamidas pirazolo-piperidina substituídas altamente ativas inovadoras ativas contra o vírus da hepatite b (hbv)
AU2019245403B2 (en) * 2018-03-29 2025-02-06 Board Of Regents, The University Of Texas System Imidazopiperazine inhibitors of transcription activating proteins
WO2019195846A1 (en) 2018-04-06 2019-10-10 Board Of Regents, The University Of Texas System Imidazopiperazinone inhibitors of transcription activating proteins
GB201806320D0 (en) * 2018-04-18 2018-05-30 Cellcentric Ltd Process
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
EP3587418B1 (en) * 2018-06-29 2021-09-01 Forma Therapeutics, Inc. Inhibitors of creb binding protein (cbp)
KR20250067962A (ko) * 2018-06-29 2025-05-15 포르마 세라퓨틱스 인크. Creb 결합 단백질(cbp)의 저해
CN109187832B (zh) * 2018-09-30 2021-07-30 华润三九医药股份有限公司 Lc-ms/ms测定去氧肾上腺素浓度的方法及样品的前处理方法
GB201818750D0 (en) 2018-11-16 2019-01-02 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
CN111320621B (zh) * 2018-12-14 2022-10-04 中国科学院广州生物医药与健康研究院 一种吲嗪类化合物及其制备方法和应用
TWI850342B (zh) * 2019-02-27 2024-08-01 美商星座製藥公司 P300/cbp hat抑制劑及其使用方法
WO2020173440A1 (en) * 2019-02-27 2020-09-03 Cullgen (Shanghai), Inc. Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use
BR112021018266A2 (pt) * 2019-03-15 2022-02-01 Forma Therapeutics Inc Composições e métodos para tratar formas positivas de receptor andrógeno de câncer
US12351577B2 (en) 2019-03-15 2025-07-08 Forma Therapeutics, Inc. Inhibiting cyclic AMP-responsive element-binding protein (CREB)
US20220227760A1 (en) * 2019-05-29 2022-07-21 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN110170052B (zh) * 2019-06-21 2020-07-10 复旦大学 Cbp-p300抑制剂在肠道损伤疾病中的应用
TW202120095A (zh) * 2019-08-05 2021-06-01 美商美國禮來大藥廠 7,8-二氫-4H-吡唑并[4,3-c]氮呯-6-酮化合物
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
WO2021213521A1 (zh) * 2020-04-25 2021-10-28 南京药石科技股份有限公司 Cbp/ep300抑制剂及其用途
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CN116507333B (zh) * 2020-08-27 2025-05-09 上海睿跃生物科技有限公司 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
CN116348112A (zh) * 2020-10-02 2023-06-27 德州大学系统董事会 转录激活蛋白的咪唑并哌嗪抑制剂
JP2023544173A (ja) 2020-10-02 2023-10-20 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム 転写活性化タンパク質のイミダゾピペラジン阻害剤
JPWO2022138944A1 (enExample) * 2020-12-25 2022-06-30
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
AU2022271550B2 (en) * 2021-05-14 2026-03-12 Wuhan Ll Science And Technology Development Co., Ltd. Acid addition salt of rock inhibitor, and crystal form, composition and pharmaceutical use thereof
AR127646A1 (es) 2021-11-12 2024-02-14 Insilico Medicine Ip Ltd Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
CN117843618A (zh) * 2022-08-29 2024-04-09 北京沐华生物科技有限责任公司 一种ep300/cbp调节剂及其制备方法和用途
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
WO2025001864A1 (en) * 2023-06-30 2025-01-02 Beijing Double-Crane Runchuang Technology Co., Ltd. Fascin inhibitors
CN117069956B (zh) * 2023-08-22 2025-04-08 南京科技职业学院 一种具有一维超分子结构的手性膦镍(ii)配合物及其制备方法和应用
WO2025111184A1 (en) 2023-11-21 2025-05-30 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides
WO2025108411A1 (zh) * 2023-11-24 2025-05-30 北京沐华生物科技有限责任公司 一种ep300/cbp调节剂及其制备方法和用途
WO2025222158A1 (en) * 2024-04-19 2025-10-23 Foghorn Therapeutics Inc. Compounds and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
CA2066428C (en) 1989-09-08 2000-11-28 Bert Vogelstein Structural alterations of the egf receptor gene in human gliomas
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DK0659439T3 (da) 1993-12-24 2002-01-14 Merck Patent Gmbh Immunkonjugater
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
HU216142B (hu) 1994-07-21 1999-04-28 Akzo Nobel N.V. Ciklusos keton-peroxidokat tartalmazó kompozíciók, és azok alkalmazása (ko)polimerek módosítására
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
EP0836605B1 (en) 1995-07-06 2002-02-06 Novartis AG Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
DE69716916T2 (de) 1996-07-13 2003-07-03 Glaxo Group Ltd., Greenford Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2201484T3 (es) 1997-05-06 2004-03-16 Wyeth Holdings Corporation Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal.
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
NZ503991A (en) 1997-11-06 2001-11-30 American Cyanamid Co Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
ES2188254T3 (es) 1998-11-19 2003-06-16 Warner Lambert Co N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas.
EP1527074A1 (en) 2002-07-25 2005-05-04 Pharmacia Italia S.p.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
CA2493625A1 (en) 2002-07-25 2004-02-19 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP2006519816A (ja) 2003-03-11 2006-08-31 ファルマシア・イタリア・ソシエタ・ペル・アツィオーニ キナーゼ阻害剤として活性なビシクロピラゾール誘導体、それらの製造方法、及びそれらを含んでなる医薬組成物
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
AU2006326134B2 (en) 2005-12-12 2012-07-19 Nerviano Medical Sciences S.R.L. Substituted pyrazolo [4,3-c] pyridine derivatives active as kinase inhibitors
WO2007099166A1 (en) 2006-03-03 2007-09-07 Nerviano Medical Sciences S.R.L. Pyrazolo-pyridine derivatives active as kinase inhibitors
US8476260B2 (en) * 2007-12-28 2013-07-02 Mitsubishi Tanabe Pharma Corporation Antitumor agent
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CL2009001158A1 (es) 2008-05-15 2009-10-23 Nerviano Medical Sciences Srl Compuestos derivados de los acidos carboxilicos, tales como 5,6-dihiro-4h-pirrolo[3,4-c]pirazol, furo[3,2-c]pirazol, tieno[2,3-c]pirazol, 4,5,6,7-tetrahidropirazol[4,3-c]piridina e indazol; composicion farmaceutica; y su uso en el tratamiento de trastornos proliferativos celulares asociados a la actividad de proteina quinasa alterada, tal como el cancer.
JP2012500652A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド 標的化共刺激ポリペプチドおよび癌を処置するための使用方法
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
CN101812063B (zh) 2010-03-18 2012-04-25 中国医学科学院医药生物技术研究所 α-萘磺酰胺基五元杂环类化合物及其抑瘤活性
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2013148114A1 (en) * 2012-03-30 2013-10-03 University Of Florida Research Foundation, Inc. P300/cbp inhibitors and methods of use
WO2014138727A1 (en) * 2013-03-08 2014-09-12 Board Of Regents, The University Of Texas System Suppression of malignant mesothelioma by overexpression or stimulation of endothelial protein c receptors (epcr)

Similar Documents

Publication Publication Date Title
JP2017530176A5 (enExample)
JP2019516757A5 (enExample)
JP2019516759A5 (enExample)
JP2017526696A5 (enExample)
JP2017533250A5 (enExample)
JP2017525740A5 (enExample)
JP2017533249A5 (enExample)
JP6835472B2 (ja) 癌の処置のための組成物
AU2017200269B2 (en) Methods of using c-Met modulators
JP2018501287A5 (enExample)
CN102985403B (zh) 具有抗雄激素性质的新型芳基酰胺衍生物
Li et al. Discovery of novel quinazolines as potential anti-tubulin agents occupying three zones of colchicine domain
ZA200307665B (en) Combination comprising N-{5-[4-(4-methyl-piperazinomethyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and a chemotherapeutic agent.
JP2018507191A5 (enExample)
JP2019529444A5 (enExample)
KR20140025433A (ko) Akt 억제제 화합물 및 베무라페닙의 조합물, 및 사용 방법
JP2014506601A5 (enExample)
RU2020131507A (ru) Имидазопиперазиновые ингибиторы белков-активаторов транскрипции
US20220160672A1 (en) Pharmaceutical compositions for modulating a kinase cascade and methods of use thereof
IL191803A (en) Substances that bind intracranial receptors
CN109843872A (zh) 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物
TW201016671A (en) Novel imidazolidine compounds as androgen receptor modulators
JP2011521938A5 (enExample)
CA2604907A1 (en) Combination cancer therapy with bis(thiohydrazide) amide compounds
JP2012514019A (ja) トルイジンスルホンアミド、及び阻害剤としてのそれらの使用